Exicure Inc Stock Other OTC
Equities
US30205M1018
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | -483K | Sales 2022 | 28.83M | Capitalization | 5.71M |
---|---|---|---|---|---|
Net income 2021 | -64M | Net income 2022 | -2M | EV / Sales 2021 | 8.21 x |
Net cash position 2021 | 24.4M | Net cash position 2022 | 1.27M | EV / Sales 2022 | 0.15 x |
P/E ratio 2021 |
-0.28
x | P/E ratio 2022 |
-2.06
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 54.96% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Kang
CEO | Chief Executive Officer | 63 | 23-02-23 |
Ji-Young Hwang
DFI | Director of Finance/CFO | 47 | 22-11-30 |
Investor Relations Contact | 47 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ji-Young Hwang
DFI | Director of Finance/CFO | 47 | 22-11-30 |
Paul Kang
CEO | Chief Executive Officer | 63 | 23-02-23 |
Hyuk Joon Ko
BRD | Director/Board Member | - | 23-08-22 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |